uniQure Gelecekteki Büyüme

Future kriter kontrolleri 2/6

uniQure kazanç ve gelirinin sırasıyla yıllık 17.1% ve 35.8% oranında artması tahmin edilirken, EPS'nin yıllık 21.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

17.1%

Kazanç büyüme oranı

21.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	35.8%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	07 Nov 2024

Gelecekteki son büyüme güncellemeleri

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03

Recent updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 09

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03

uniQure: The Valuation Got More Attractive

Feb 01

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

Jan 17

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Jul 02

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

Jun 28

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 14

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Apr 11

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Mar 01

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Dec 09

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug 08

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Apr 08

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23

uniQure: Betting On Hemophilia-B Cure

Jan 18

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:QURE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	93	-126	-80	-71	10
12/31/2025	41	-141	-53	-83	13
12/31/2024	39	-194	-157	-152	13
9/30/2024	29	-240	-185	-179	N/A
6/30/2024	28	-285	-111	-104	N/A
3/31/2024	19	-297	-135	-128	N/A
12/31/2023	16	-308	-153	-146	N/A
9/30/2023	112	-228	-161	-151	N/A
6/30/2023	112	-187	-251	-239	N/A
3/31/2023	110	-157	-214	-198	N/A
12/31/2022	106	-127	-163	-145	N/A
9/30/2022	61	-125	-154	-137	N/A
6/30/2022	62	-114	-149	-129	N/A
3/31/2022	525	324	286	304	N/A
12/31/2021	524	330	271	288	N/A
9/30/2021	500	321	281	298	N/A
6/30/2021	500	303	292	303	N/A
3/31/2021	38	-139	-154	-143	N/A
12/31/2020	38	-125	-144	-135	N/A
9/30/2020	6	-166	-132	-124	N/A
6/30/2020	5	-136	-120	-111	N/A
3/31/2020	6	-124	-114	-105	N/A
12/31/2019	7	-124	-105	-99	N/A
9/30/2019	6	-105	-96	-91	N/A
6/30/2019	8	-103	-93	-89	N/A
3/31/2019	9	-92	-86	-81	N/A
12/31/2018	11	-83	-80	-76	N/A
9/30/2018	12	-90	-81	-76	N/A
6/30/2018	11	-78	N/A	-71	N/A
3/31/2018	13	-78	N/A	-74	N/A
12/31/2017	13	-79	N/A	-64	N/A
9/30/2017	20	-67	N/A	-62	N/A
6/30/2017	25	-72	N/A	-65	N/A
3/31/2017	24	-71	N/A	-68	N/A
12/31/2016	25	-73	N/A	-72	N/A
9/30/2016	20	-76	N/A	-81	N/A
6/30/2016	16	-90	N/A	-62	N/A
3/31/2016	14	-90	N/A	5	N/A
12/31/2015	11	-82	N/A	7	N/A
9/30/2015	8	-76	N/A	22	N/A
6/30/2015	6	-58	N/A	13	N/A
3/31/2015	5	-45	N/A	-35	N/A
12/31/2014	6	-50	N/A	-37	N/A
9/30/2014	5	-41	N/A	-29	N/A
6/30/2014	6	-42	N/A	-6	N/A
3/31/2014	6	-41	N/A	-7	N/A
12/31/2013	4	-37	N/A	-6	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: QURE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: QURE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: QURE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: QURE şirketinin gelirinin (yıllık 35.8% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: QURE şirketinin gelirinin (yıllık 35.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: QURE 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

uniQure Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates decrease by 14%, EPS upgraded

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Consensus revenue estimates fall by 15%

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Consensus revenue estimates decrease by 33%, EPS upgraded

Consensus revenue estimates fall by 35%

Recent updates

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS

Consensus revenue estimates decrease by 14%, EPS upgraded

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

New minor risk - Shareholder dilution

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Uniqure N.V. Announces Executive Changes

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 15%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

uniQure N.V., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold US$177k worth of stock

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates decrease by 33%, EPS upgraded

New minor risk - Share price stability

uniQure: The Valuation Got More Attractive

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Consensus revenue estimates fall by 35%

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 55%

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Operating Officer notifies of intention to sell stock

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. Announces Executive Changes

New minor risk - Share price stability

Consensus revenue estimates increase by 12%

Consensus revenue estimates fall by 36%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

CEO & Executive Director notifies of intention to sell stock

Consensus EPS estimates fall by 16%

CEO & Executive Director recently sold US$493k worth of stock

CEO & Executive Director notifies of intention to sell stock

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Independent Non-Executive Director exercised options and sold US$103k worth of stock

Independent Non-Executive Director exercised options and sold US$143k worth of stock

CEO & Executive Director recently sold US$149k worth of stock

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Independent Non-Executive Director notifies of intention to sell stock

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Consensus revenue estimates fall by 51%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind